Aquestive Therapeutics/$AQST

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Aquestive Therapeutics

Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.

Ticker

$AQST
Sector
Primary listing

Employees

142

AQST Metrics

BasicAdvanced
$722M
-
-$0.69
1.99
-

What the Analysts think about AQST

Analyst ratings (Buy, Hold, Sell) for Aquestive Therapeutics stock.

Bulls say / Bears say

The FDA accepted the New Drug Application for Anaphylm™ with a PDUFA date of January 31, 2026, positioning Aquestive to launch the first oral epinephrine film for anaphylaxis if approved.
Aquestive had a pro forma cash position of about $93.0 million as of December 31, 2024, including $21.4 million raised through its ATM facility, giving the company enough runway for near-term clinical and commercial milestones.
The AQST-108 epinephrine topical gel Phase 2a clinical trial is on track to begin in Q2 2025, expanding the company's proprietary pipeline beyond CNS and strengthening its differentiated drug delivery platform.
Aquestive reduced its full-year 2025 revenue guidance to $44–$50 million after Libervant shifted from full approval to tentative approval, highlighting execution and regulatory risks in the CNS pipeline.
First-quarter 2025 revenue dropped 28 percent year-over-year to $8.7 million, due to declines in Suboxone and royalty income, showing the company’s dependence on legacy licensed products amid pipeline delays.
Net loss widened to $22.9 million in Q1 2025 from $12.8 million a year earlier, and SG&A expenses rose to $19.1 million, raising concerns about cash burn ahead of potential Anaphylm approval.
Data summarised monthly by Lightyear AI. Last updated on 7 Oct 2025.

AQST Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

AQST Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $AQST

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs